Grifols, S.A. (NASDAQ:GRFS) Shares Acquired by Hantz Financial Services Inc.

Hantz Financial Services Inc. lifted its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 23.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 241,812 shares of the biotechnology company’s stock after acquiring an additional 45,997 shares during the period. Hantz Financial Services Inc.’s holdings in Grifols were worth $2,147,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in GRFS. GAMMA Investing LLC lifted its position in shares of Grifols by 49.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after buying an additional 1,135 shares during the last quarter. Signaturefd LLC grew its stake in Grifols by 66.2% during the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock worth $48,000 after buying an additional 2,153 shares during the last quarter. AQR Capital Management LLC acquired a new position in Grifols during the second quarter worth approximately $89,000. Cetera Advisors LLC purchased a new stake in Grifols in the first quarter valued at approximately $147,000. Finally, Chesapeake Capital Corp IL purchased a new position in shares of Grifols during the third quarter worth approximately $148,000.

Grifols Stock Down 13.4 %

Shares of NASDAQ GRFS opened at $6.99 on Friday. The company’s fifty day moving average is $8.76 and its two-hundred day moving average is $8.10. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. Grifols, S.A. has a one year low of $5.30 and a one year high of $12.15.

Analysts Set New Price Targets

Separately, Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.